key: cord-1003886-lf73j759
authors: Araç, Songül; Özel, Mehmet
title: A new parameter for predict the clinical outcome of patients with COVID‐19 pneumonia: The direct/total bilirubin ratio
date: 2021-07-16
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14557
sha: 89410da6489f507e90e0160819d265be9e619bac
doc_id: 1003886
cord_uid: lf73j759

AIM: An urgent need to define clinical and laboratory parameters to predict progression to the severe and lethal forms of Coronavirus Disease 2019 (COVID‐19). To investigate the direct/total bilirubin ratio (D/TBil), as a novel parameter, to predict the poor survival of COVID‐19 Pneumonia. METHODS: The clinical characteristics and laboratory parameters of hospitalised COVID‐19 pneumonia patients were analysed from 20 March to August 1, 2020, in a tertiary hospital, retrospectively. All remarkable variables were selected for a forward stepwise binary logistic regression analysis to define the independent risk factors for mortality. RESULTS: 537 (248 women and 289 men) patients were separated into two groups for analysis: survivors vs deceased. The mean age of the deceased group was statistically significantly higher than the survivor group 72 (30‐92) years vs 50 (18‐97) years (P < .001). D/TBil, age, gender, hypertension and neutrophil‐to‐lymphocyte ratio (NLR) variables contributed significantly to the binary logistic regression model. The mortality risk increased 14.6 times in patients with D/TBil > 0.5, and 2.4 times in patients with NLR > 4. CONCLUSION: D/TBil > 0.5 was associated with a novel parameter to poor survival of COVID‐19 on admission. Also, the combination of age, gender, the presence of hypertension, D/TBil and NLR contributed significantly to predicting the poor survival of COVID‐19.

suggested DBil had a more accurate predictive value than TBil in patients with sepsis. 14 However, the relationship between bilirubin with poor clinical outcomes has not been yet well described in COVID-19 patients.

In this study, we analysed the early clinical presentation, basic laboratory findings and clinical outcomes in our emergency department patients who were hospitalised diagnosed with COVID-19 pneumonia. Our aim was to investigate the direct/total bilirubin ratio (D/TBil), as a novel parameter to predict the poor survival of COVID-19 pneumonia.

Gazi Yasargil Training and Research Hospital as a tertiary hospital des- The definition of the survivor group-patients were discharged from the hospital; the definition of the deceased group-patients were dead during hospitalisation. We examined the electronic medical records. Sociodemographic information such as age, gender as well as past medical histories such as hypertension, diabetes mellitus, cardiac disease, and chronic obstructive pulmonary disease, chronic kidney disease, malignancy, vitals, clinical symptoms, laboratory results and clinical outcomes were collected. Nasopharyngeal swab samples were collected and used in the RT-PCR assay for the detection of SARS-CoV-2 viral nucleic acid. Laboratory variables were tested with usual methods, including complete blood count (CBC) with differential, albumin, aminotransferases (AST and ALT), lactate dehydrogenase (LDH), C-reactive protein (CRP), blood urea nitrogen, creatinine, direct bilirubin (DBil), total bilirubin (TBil), d-dimer, cardiac troponin I. All patients' laboratory data were collected from their first laboratory test on admission to ED. Also, we calculated the D/TBil, neutrophil-to-lymphocyte ratio (NLR), and platelet-tolymphocyte ratio (PLR) of all patients. All data were primarily analysed by trained physicians. Stepwise, by forward selection, binary logistic regression was performed with COVID-19 outcome of survival or death as independent variables. All significant variables were added to model, but only those that made remarkable contributions remained in the model. In this regression model, D/TBil, age, gender, presence of hypertension, and NLR were used as independent variables to determine significant predictors for COVID-19 mortality.

Receiver operating characteristic (ROC) analysis was used to determine the cut-off value of the laboratory parameters in the established model. A P value of < 0.05 was considered significant for all analyses. survivor group 72 (min-max, 30-92) years vs 50 (min-max, 18-97) years (P < .001). The prevalence of comorbidities such as hypertension and diabetes in the deceased group was statistically significantly higher than the survivor (P < .001 and P = .003). Demographic data, presence of comorbidities and outcomes of patients were displayed in Table 1 .

According to the results of haematologic parameters performed on admission, the deceased group compared with the survivor group had more significan increases in white blood cell count (WBC), neutrophil, lymphocyte, NLR, PLR (all of P < .001) and more significant decreases in haemoglobin (HGB) and haematocrit (HCT) levels (P = .014 and P = .008). Also according to the results of biochemical and the other parameters performed on admission, the deceased group compared with the survivor group had more significant increases in DBil, D/TBil, aspartate aminotransferase (AST), LDH, CRP, blood urea nitrogen, creatinine, d-dimer, cardiac troponin I (P < .001, respectively) and a more significant decrease in albumin level (P < .001). Laboratory parameters performed on the admission of patients were displayed in Table 2 .

Logistic regression analysis was performed with demographic data, presence of comorbidity and laboratory parameters for estimating the probability of our patients dying of COVID-19 in this study. We noticed that D/TBil, age, gender, hypertension and NLR variables contributed significantly to the binary logistic regression model ( Table 3 ). The cut-off value for the independent variables such as D/TBil and NLR in the model was determined using ROC analysis (Table 4 ). The D/TBil cut-off value of 0.5 was differentiated between deceased and survivor groups (area under the curve (AUC): 0.858, 75.8% sensitivity, 85.8% specificity) and NLR cut-off value of 4.03 was differentiated between deceased and survivor groups (AUC: 0.729, 68% sensitivity, 65.8% specificity). In our model, the mortality risk increased 14.6 times in patients with D/TBil value greater than 0.5, and the mortality risk increased 2.4 times in patients with NLR value greater than 4 (Table 3) . According to our model, when D/ TBil is used as a stand-alone explanatory variable for estimating the likelihood of in COVID-19 patients having an outcome of survival or death, the explanatory rate was 24.9%. The total explanatory rate of all explanatory variables in our model was 37.8% (Table 3) .

According to the comparison of D/TBil value of our patients with age-standardised mortality rates in our model, if patients had D/TBil value > 0.5 with above 50 years of age, the mortality rate was 63.1%, and if patients had D/TBil value < 0.5 with above 50 years of age, the mortality rate was 12.6%. On the other hand, if patients had D/ TBil value > 0.5 with under 50 years of age, the mortality rate was 21%, and if patients had D/TBil value < 0.5 with under 50 years of age, the mortality rate was 0%. According to our model, in the above 50 years old patients, had D/TBil value > 0.5, was increased the mortality risk 11.83 times ( According to a multicentre retrospective study, Fu et al 21 Also, they suggested that serum bilirubin was an early and sensitive biochemical marker for predicting sepsis-related ARDS. 22 Wu et al 14 conducted a study of patients with sepsis, and they noticed that the prognosis was associated particularly with DBil rather than TBil. Also, they suggested that DBil had a more accurate predictive value than TBil in patients with sepsis. 14 Our study is compatible with the literature. Additionally, our study showed that D/TBil can be used as an independent parameter for estimating the likelihood of COVID-19 patients' outcome of survival or death. According to the literature and the findings in our study, bilirubin is a useful tool to evaluate the severity and extent of COVID-19 pneumonia.

In our study, patients in the deceased group were older than the survivor group and had more underlying comorbidities such as hypertension and diabetes. Dong et al 23 suggested that age and comorbidity can be associated with increased mortality and poor outcomes in patients diagnosed with COVID-19 pneumonia.

Advanced age and presence of diabetes were previously noticed to be remarkably correlated with raised incidence, the severity of disease, likewise the risk of mortality in COVID-19. 24 As the SARS-CoV-2 outbreak progresses, recent studies conducted with COVID-19 patients noticed that useful blood biomarkers, which were found to be associated with the severity and prognosis of COVID-19 pneumonia. [4] [5] [6] [7] In our study, we analysed hematologic, biochemical and inflammatory biomarker test results and noticed some biomarker abnormalities that were found between deceased and survivor groups, which may enable significant recognition for poor prognosis. In our study, we found that NLR was the most effective haematological parameter for predicting poor outcomes. Also, we noticed that the combination of D/TBil and NLR parameters contributed significantly to predicting the poor survival of COVID-19. The NLR was a widely used biomarker for evaluating the gravity of bacterial infections and predicting the prognosis of patients with pneumonia. 28, 29 In recent studies, it has been determined that haematological parameters such as NLR and 

This study had several limitations. Our study was conducted in a single centre with a relatively small patient group. We are incapable of examining the mechanisms of our findings because of the retrospective condition of our study. Also, we used demographic data, the presence of comorbidity and laboratory parameters to determine the prognosis of COVID-19. However, we did not include imaging features for lung involvement of COVID-19 pneumonia to determine the prognosis of COVID-19. Although our study was retrospective, we did not use a specific cut-off in time to define in-hospital mortality. We paid attention to the in-hospital mortality situation at any time rather than the duration of the mortality in fatal pandemic. Additional prospective, long-term and large-scale studies are needed to verify the reliability of the D/TBil as an independent prediction parameter for poor survival in COVID-19 patients.

On hospital admission, we identified a novel parameter D/TBil above 0.5 as associated with poor clinical outcomes such as mortality in hospitalised patients diagnosed with COVID-19 pneumonia at an early stage. Also, we noticed in our study that combination of age, gender, and hypertension, D/TBil, and NLR contributed significantly to predicting the poor survival of COVID-19.

All patients gave their consent to participate in the study.

The authors have obtained consent to publish from the participant (or legal parent or guardian for children) to report individual patient data.

The authors declare that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality. Moreover, the authors ensure that their datasets are presented in the main manuscript.

All authors certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received or pending), are the following: None. 

SA and MÖ were responsible for the study design study supervision, data analysis and manuscript writing. The authors confirm that all listed authors meet the authorship criteria and that all authors are in agreement with the content of the manuscript.

Education and Research Hospital with the decision numbered 530 and dated July 24, 2020. Written informed consent was obtained from all participants at each stage of the study.

Songül Araç https://orcid.org/0000-0001-6830-3639

Mehmet Özel https://orcid.org/0000-0002-4797-7017

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

disea ses/n ovel-coron aviru s-2019/techn ical-guida nce/namin g-the-coron aviru s-disea se-(covid -2019)-and-the-virus -that-cause s-it

Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou. China

Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan

A major outbreak of severe acute respiratory syndrome in Hong Kong

Is albumin predictor of mortality in COVID-19?

Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count

The correlation between serum total bilirubin and outcomes in patients with different subtypes of coronary artery disease

Circulating bilirubin and defense against kidney disease and cardiovascular mortality: Mechanisms contributing to protection in clinical investigations

Bilirubin: an endogenous molecule with antiviral activity in vitro

Targeting the hemeheme oxygenase system to prevent severe complications following COVID-19 ınfections

The association of serum bilirubin levels on the outcomes of severe sepsis

Direct bilirubin as a prognostic biomarker in enteric fistula patients complicated with sepsis: a casecontrol study

Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV ınfection. Epub ahead of print 2020

Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov doi: bioRxiv preprint

The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. Epub ahead of print 2020

COVID-19 and liver disease

Molecular basis of bilirubin-induced neurotoxicity

Bilirubin-induced cell toxicity involves PTEN activation through an APE1/Ref-1-dependent pathway

Clinical features of patients infected with coronavirus disease 2019 with elevated liver biochemistries: A multicenter, retrospective study

Serum bilirubin levels on ICU admission are associated with ARDS development and mortality in sepsis

Prediction for progression risk in patients with COVID-19 pneumonia: the CALL Score. Clin İnf Dis. Epub ahead of print

Prediction models for diagnosis and prognosis of covid-19: Systematic review and critical appraisal

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan

Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis

T-cell immunity of SARS-CoV: ımplications for vaccine development against MERS-CoV

The role of neutrophil to lymphocyte count ratio in the differential diagnosis of pulmonary tuberculosis and bacterial community-acquired pneumonia: a crosssectional study at Ayder and Mekelle Hospitals

Leucocyte subsets effectively predict the clinical outcome of patients with COVID-19 pneumonia: a retrospective case-control study

Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters

How to cite this article: Araç S, Özel M. A new parameter for predict the clinical outcome of patients with COVID-19 pneumonia: The direct/total bilirubin ratio